The FDA on Friday approved aficamten (Myqorzo) for symptomatic obstructive hypertrophic cardiomyopathy (HCM), drugmaker Cytokinetics announced. Aficamten is an allosteric and reversible inhibitor of ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved aficamten to improve functional capacity and symptoms in adults with obstructive hypertrophic ...
ROSELAND, N.J., Dec. 9, 2025 /PRNewswire/ -- ADP, a global leader in HR and payroll solutions, today announced the finalists for the 2026 HCM Distinction Awards. Celebrating the transformation of work ...
CHARLOTTE, N.C. and STAMFORD, Conn., Oct. 20, 2025 (GLOBE NEWSWIRE) -- HCM II Acquisition Corp. (Nasdaq: HOND) (“HCM II”), a special-purpose acquisition company, is pleased to announce that in an ...
Most people with HCM can participate in mild- to moderate-intensity exercise safely. When it comes to vigorous exercise and competitive sports, there may be a need for additional guidance from your ...
MINNEAPOLIS — Readouts of data on an experimental drug for hypertrophic cardiomyopathies showed the agent appeared safe and effective in long-term treatment and can significantly improve exercise ...
CHARLOTTE, N.C. & STAMFORD, Conn.--(BUSINESS WIRE)--HCM II Acquisition Corp. (Nasdaq: HOND) (“HCM II”), a special-purpose acquisition company and Terrestrial ...
Oracle Corp. today announced a series of new agentic artificial intelligence extensions to its Fusion Cloud Human Capital Management suite, bringing the number of agents in the application to more ...
MADRID, Spain—For patients with hypertrophic cardiomyopathy (HCM), research presented today at the European Society of Cardiology (ESC) Congress 2025 demonstrated both the promise and the potential ...
Panel A shows a cross-section of a normal heart (top) and an endomyocardial biopsy sample from a normal heart (bottom; with hematoxylin and eosin staining) that shows normal histologic characteristics ...
In one of two trials that substantially expand clinical evidence with myosin inhibitors in the treatment of hypertrophic cardiomyopathy (HCM), a next-in-class agent beat beta-blockers in first-line ...
Cytokinetics drug yielded benefits over common therapy in patients with heart condition, study shows
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback